Were Joseph Loscalzo’s Ionis (IONS) share sales under a 10b5-1 plan?

Yes. The filing states the shares were sold under a Rule 10b5-1 trading plan. This plan was adopted by the reporting person on November 18, 2025, allowing pre-scheduled trades that proceed automatically regardless of subsequent market or company developments.

Ionis director logs option exercises and share sales

Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March. He exercised non-qualified stock options to receive common shares at an exercise price of $38.06 per share, then sold 1,032 common shares at weighted average prices around $80–$81.

The sales, executed on March 3–4, 2026, were carried out under a pre-established Rule 10b5-1 trading plan. After these transactions, Loscalzo directly owned 36,330 common shares of Ionis Pharmaceuticals.

Insider Trade Summary

Exercise and Sale: 1,032 shares ($44K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider LOSCALZO JOSEPH

Role Director

Sold 1,032 shs ($83K)

Approx. gross sale proceeds $83K

Approx. exercise cost $39K

Approx. pre-tax spread $44K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	200	$0.00	$0.00
Exercise	Common Stock	200	$38.06	$8K
Sale	Common Stock	200	$80.00	$16K
Exercise	Non-Qualified Stock Option (right to buy)	832	$0.00	$0.00
Exercise	Common Stock	832	$38.06	$32K
Sale	Common Stock	832	$80.3279	$67K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 10,968 contracts (Direct); Common Stock — 36,330 shares (Direct)

Footnotes (2)

F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.035 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Ionis (IONS) director Joseph Loscalzo report?

Joseph Loscalzo reported exercising stock options and selling Ionis shares. He converted options into common stock at an exercise price of $38.06 per share, then sold 1,032 common shares in open-market transactions at weighted average prices around $80–$81.

How many Ionis (IONS) shares did Joseph Loscalzo sell in this Form 4?

The Form 4 shows Loscalzo sold 1,032 Ionis common shares. These sales occurred in multiple transactions on March 3–4, 2026, at weighted average prices ranging from about $80.04 to $81.01 per share, as detailed in the filing’s footnote disclosure.

What prices did Ionis (IONS) director Joseph Loscalzo receive for the sold shares?

The reported sale prices are weighted averages around $80–$81 per Ionis share. One transaction shows an average price of $80.00, while another reflects $80.3279, with individual trades executed between $80.035 and $81.01, as described in the Form 4 footnote.

How many Ionis (IONS) shares does Joseph Loscalzo own after these transactions?

After the reported transactions, Loscalzo directly owned 36,330 Ionis common shares. This figure reflects his direct holdings following the option exercises and related open-market sales disclosed for March 3–4, 2026, in the Form 4 filing.

What type of derivative security did Joseph Loscalzo exercise at Ionis (IONS)?

Loscalzo exercised non-qualified stock options described as a “Non-Qualified Stock Option (right to buy).” These options were converted into Ionis common stock through derivative exercise transactions, with the underlying shares then partially sold in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/05/2026 - 06:14 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOSCALZO JOSEPH

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		M		832	A	$38.06	37,162	D
Common Stock	03/03/2026		S		832⁽¹⁾	D	$80.3279⁽²⁾	36,330	D
Common Stock	03/04/2026		M		200	A	$38.06	36,530	D
Common Stock	03/04/2026		S		200⁽¹⁾	D	$80	36,330	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$38.06	03/03/2026		M			832	07/01/2023	06/30/2032	Common Stock	832	$0.0	11,168	D
Non-Qualified Stock Option (right to buy)	$38.06	03/04/2026		M			200	07/01/2023	06/30/2032	Common Stock	200	$0.0	10,968	D

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.035 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Joseph Loscalzo	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR